Jefferson Capital, Inc. (JCAP)

On our desk, we are closely tracking JCAP's valuation following Truist Securities' price target bump to $30 from $26. With a market cap around $1.28 billion and a leverage ratio improving to 1.71x from 1.76x, the equity narrative looks increasingly solid. The 55.6% positive sentiment trend on Wall St. Rank aligns nicely with the 18% YoY growth in both total collections ($300.9M) and ERC ($3.4B). The recent $100 million senior notes pricing due 2030 also gives them adequate liquidity headroom to keep acquiring portfolios without stressing near-term cash flows.

When evaluating management's execution during the Q2 2026 earnings call, analysts should probe David Burton and Christo Realov on the integration and long-term yield of the Bluestem and Conn's portfolios. These acquisitions are clearly carrying the heavy lifting for the 18% collection increase, but understanding the vintage quality and expected decay curves of these specific active and insolvency consumer accounts is vital for validating the $3.4 billion ERC figure. Focus your underwriting questions on how sustained macroeconomic shifts might impact their 72.2% cash efficiency ratio moving forward.

Looking at the risk matrix on my screen, investors need to keep a close eye on the earnings trajectory. While Q2 2026 adjusted EPS came in at $0.77 (beating the Zacks consensus of $0.63), the GAAP EPS of $0.67 is down compared to $0.81 a year ago. Furthermore, looking back at Q1, there was a notable negative earnings surprise of -23.75%. Even though portfolio deployments are up 21% to $152.2 million and the cash efficiency ratio sits at a healthy 72.2%, the underlying volatility in quarterly EPS performance warrants strict risk management.